Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

SELL
$0.79 - $2.39 $82 - $250
-105 Reduced 75.0%
35 $0
Q3 2022

Nov 14, 2022

BUY
$2.26 - $3.38 $316 - $473
140 New
140 $0
Q1 2022

May 16, 2022

SELL
$2.8 - $5.23 $2,800 - $5,230
-1,000 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$9.79 - $17.86 $9,790 - $17,860
1,000 New
1,000 $10,000

Others Institutions Holding ACHL

About Achilles Therapeutics plc


  • Ticker ACHL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,774,000
  • Market Cap $47.3M
  • Description
  • Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in ...
More about ACHL
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.